Novel iron-based phosphate binders in patients with chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 4, 2015, Pages 330-335

  Shah, Hitesh H ^a,b   Hazzan, Azzour D ^a,b   Fishbane, Steven ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Chronic kidney disease; Dialysis; Iron; Phosphate; Phosphate binders

Indexed keywords

FERRIC CITRATE; PHOSPHATE; PLACEBO; SEVELAMER CARBONATE; SUCROFERRIC OXYHYDROXIDE; CHELATING AGENT; IRON;

CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY (TOPIC); PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; UNITED STATES; BLOOD; HEMODIALYSIS; HYPERPHOSPHATEMIA; METABOLISM; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC;

CHELATING AGENTS; HUMANS; HYPERPHOSPHATEMIA; IRON; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942750404     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000128     Document Type: Review

References (36)

1. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
2. Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients. Nephrol Dial Transplant 2007;22:2909-2916.
3. Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-396.
4. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
5. Mathew S, Tustison KS, Sugatani T, et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008;19:1092-1105.
6. Ghazali A, Ben Hamida F, Bouzernidj M, et al. Management of hyperphosphatemia in patients with renal failure. Curr Opin Nephrol Hypertens 1993;2:566-579.
7. Yu Gc, Lee DBN. clinical disorders of phosphorus metabolism. West J Med 1987;147:569-576.
8. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312-1324.
9. Lee DBN, Brautbar N, Kleeman CR. Disorders of phosphorus metabolism. In: Bronner F, Coburn JN, editors. Disorders of mineral metabolism: pathophysiology of calcium, phosphorus and magnesium, Vol 3. New York: Academic Pres; 1981. pp. 283-390.
10. Wilkinson R. Absorption of calcium, phosphorus and magnesium. In: Nordin BEC, editor. Calcium, phosphate and magnesium metabolism. Edinburg and London: Churchill-Livingstone; 1976. pp. 36-112.
11. Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bonedisorder. Kidney Int 2011;79(Suppl 121):S3-S8.
12. Knox FG, Oswald H, Marchand GR, et al. Phosphate transport along the nephron. Am J Physiol 1977;233:F261-F268.
13. Bricker NS. On the pathogenesis of the uremic state. An exposition of the 'trade of hypothesis'. N Engl J Med 1972;286:1093-1099.
14. Hou SH, Zhao J, Ellman CF. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991;18:217-224.
15. Chauveau P, Poigent JL, Kuno T. Phosphate removal rate: a comparative study of five high flux dialysers. Nephrol Dial Transplant 1991;6(Suppl 2):114-115.
16. Desoi A, Umans J. Phosphate kinetics during high flux hemodialysis. J Am Soc Nephrol 1993;4:1214-1218.
17. Haas T, Hillion D, Dongradi G. Phosphate kinetics in dialysis patients. Nephrol Dial Transplant 1991;6(Suppl 2):108-113.
18. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999;14:863-867.
19. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010;74:4-11.
20. Wilhelm M, Gaillard S, Rakov V, Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol 2014;81:251-258.
21. Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the ironbased phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8:280-289.
22. Floege J, Covic AC, Ketteler M, et al., PA21 Study Group. A phase III study of & the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 2014;86:638-6347. This phase III study compares the efficacy and safety of sucroferric oxyhydroxide with that of sevelamer carbonate in both HD and peritoneal dialysis patients.
23. http://auryxia.com/wp-content/uploads/Auryxia-PI-Keryx-112014.pdf. [Accessed 29 December 2014]
24. Liu SH, Chu HI. Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A. T.10) and iron. Medicine (Baltimore) 1943;22:103-161.
25. Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999;10:1274-1280.
26. Yang WC, Yang CS, Hou CC, et al. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant 2002;17:265-270.
27. Dwyer JP, Sika M, Schulman G, et al., Collaborative Study Group. Doseresponse and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013;61:759-766.
28. Lewis JB, Sika M, Koury MJ, et al., for the Collaborative Study Group. Ferric & citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 2015;26:493-503; doi: 10.1681/ASN.2014020212. [Epub ahead of print] The pivotal phase 3 study of ferric citrate was highly illuminating in terms of characterizing the drug's utility as a phosphate binder and erythropoietic agent.
29. Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014;7:191-201.
30. Markowitz GS, Kahn GA, Feingold RE, et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997;48:34-40.
31. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
32. Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305.
33. Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis 2013;62:457-473.
34. Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment & of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 2014;9:543-552. Interesting finding of a substantial reduction in FGF-23 levels during ferric citrate treatment.
35. Block GA, Fishbane S, Rodriguez M, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 2015;65:728-736; doi: 10.1053/j.ajkd.2014.10.014. [Epub ahead of print] As in the above reference [34&], a clear demonstration of ferric citrate's ability to lower FGF-23 levels.
36. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-1415.